# PROOF OF CONCEPT STUDY ON THE EFFICACY OF INHALATORY TARGETED IMATINIB NANOFORMULATIONS IN PULMONARY HYPERTENSION AND POST-INFLAMMATORY FIBROSIS.

> **NCT06917196** · — · RECRUITING · sponsor: **Fondazione IRCCS Policlinico San Matteo di Pavia** · enrollment: 16 (estimated)

## Conditions studied

- Pulmonary Arterial Hypertension (PAH)
- Lung Fibrosis Interstitial

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06917196
- **Lead sponsor:** Fondazione IRCCS Policlinico San Matteo di Pavia
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2023-12-04
- **Primary completion:** 2025-12-04
- **Final completion:** 2026-06-04
- **Target enrollment:** 16 (ESTIMATED)
- **Last updated:** 2025-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06917196

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06917196, "PROOF OF CONCEPT STUDY ON THE EFFICACY OF INHALATORY TARGETED IMATINIB NANOFORMULATIONS IN PULMONARY HYPERTENSION AND POST-INFLAMMATORY FIBROSIS.". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT06917196. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*